Response to the MBS Review Taskforce - Dermatology, Allergy and Immunology


Date: 26 July 2017

The RACGP provides comment on the Dermatology, Allergy and Immunology Clinical Committee draft report, prior to final recommendations being provided to government regarding MBS Item numbers.

Generally, the RACGP strongly supports the use of histopathology as a marker to detect cancers in skin lesions. Specific comment is provided on proposed changes to individual MBS item numbers.